Anders Kärnell


Anders is a Medical Doctor with extensive experience in pharma/biotech, spanning rare diseases, orphan drugs, hospital products and vaccines. He has served organizations ranging from start-up firms to biotech companies and big pharma in the Nordics and Europe.

Anders most recent role was at MSD as Medical Director Sweden, where he managed the medical affairs activities over the entire portfolio, including orphan drug designated products. Prior to that Anders was the Nordic Medical Lead at SPMSD in the vaccine area, and at Medivir, a Swedish biopharma company, driving the medical launch of an oral antiviral against HCV. Anders additionally supported the orphan drug firm OxThera in the development of a lifesaving therapy for an ultra-rare disease, establishing a pan-European scientific leader network.

Earlier Anders spent three years with Alexion as Vice President Development and Medical Affairs in Europe, based in France and Switzerland. He led a pan-European team building medical expertise around SolirisĀ® (eculizumab) for the treatment of PNH and other compounds in clinical development in the rare disease area. Product knowledge and disease awareness were key elements in the interactions with leading physicians across Europe.

Before joining Alexion served as the Nordic Chief Scientific Officer at Novartis, European Head of Medical Affairs at PowderJect in the UK, and in leading medical positions at SBL Vaccine and Active Biotech in Sweden.

Anders is a board-certified specialist in Infectious Diseases and Clinical Bacteriology. He started his career as practising physician at the Department of Infectious Diseases and as Head of the Department of Clinical Bacteriology at Karolinska University Hospital, Huddinge, Sweden.